Highest-materiality recent filing
Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50
Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.
Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul
Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.
Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.
Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance
Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.
Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY
Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.
Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026
Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.
Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%
Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).
Q4 2024: rev $442.6M (+11.5% rep, +3.5% org); adj EPS $0.97 vs $0.89; GAAP EPS $0.25 flat YoY.
Integra LifeSciences receives FDA warning letter for quality system violations at three facilities
FDA warning letter dated Dec 19, 2024, for quality system issues at Mansfield, MA; Plainsboro, NJ; Princeton, NJ facilities.
Integra LifeSciences names Mojdeh Poul as President & CEO effective Jan 6, 2025
Mojdeh Poul appointed President & CEO, effective January 6, 2025, succeeding Jan De Witte.
Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO
Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.
Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds
GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.
Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent
Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.
Integra LifeSciences Q4 GAAP EPS $0.25 vs $0.63; guides FY2024 revenue up 4-5% organic
Q4 revenues $397.0M, down 0.2% reported; organic revenue ex-Boston up 3.6%.
Jan De Witte to retire as President and CEO by end of 2024 after successor appointed; will remain until transition.
Integra LifeSciences to acquire Acclarent from Ethicon for $275M cash plus $5M milestone
Purchase price: $275M in cash at closing, plus $5M regulatory milestone; acquisition of all outstanding shares of Acclarent.
Integra Q3 revenues down 0.7%, GAAP EPS $0.24; adjusts FY23 guidance lower
Q3 revenue $382.4M, reported -0.7% YoY; organic ex-Boston +7.1%.
Integra LifeSciences enters $125M accelerated share repurchase with Wells Fargo
Agreement with Wells Fargo to repurchase $125M of common stock via accelerated share repurchase.
Integra Q2 adj EPS $0.71, revenue $381M (-4.2%); FDA warning on Boston facility; guides down
Q2 GAAP diluted EPS $0.05 vs $0.54; adjusted EPS $0.71 vs $0.82; revenue $381.3M declined 4.2% reported, 2.7% organic.
Integra LifeSciences initiates global product recall due to endotoxin issues, cuts guidance
Voluntary recall of SurgiMend, PriMatrix, Revize, TissueMend from Boston facility (March 2018 – May 2023).
Integra LifeSciences Q1 revenue $380.8M, organic growth 4.6%; adj EPS $0.74 flat YoY
Q1 revenues $380.8M, +1.1% reported, +4.6% organic vs Q1 2022.
Q4 2022 revenues $398.0M (-1.8% reported, +2.9% organic); GAAP EPS $0.63, adj EPS $0.94.
Integra LifeSciences raises adj EPS guidance for Q4 and FY2022 above prior expectations
Q4 2022 adjusted EPS expected $0.92-$0.96 vs $0.84 in Q4 2021; above Oct guidance high end.
Integra pre-announces Q4 rev ~$397-398M, adj EPS above guidance; FY rev ~$1,557-1,558M
Q4 2022 revenue expected $397M-$398M, down ~2% reported, up ~3% organic vs Q4 2021.
Integra to acquire SIA for up to $140M; plans $150M share buyback
Integra buys SIA for $50M at closing plus up to $90M in milestones; deal expected to close by end of 2022.
Q3 revenues $385M (-0.4% reported, +3.5% organic); GAAP EPS $0.60 (vs $0.51), adjusted EPS $0.86 (flat YoY).
Integra LifeSciences voluntarily recalls all CereLink ICP monitors; cuts guidance by $9M
Voluntary global removal of all CereLink intracranial pressure monitors due to out-of-range readings from electrical interference.
Q2 revenue $398M, +2% reported (+4.8% organic); GAAP EPS $0.54 vs $0.41; adjusted EPS $0.82 vs $0.79.
Revenues $376.6M (+4.6% reported, +5.6% organic); adjusted EPS $0.74 vs $0.69 Q1 2021; GAAP EPS $0.39 (down from $0.53, prior year included $42.9M divestiture gain).
Integra Q4 revenue $405.5M (+8.3% organic); adj EPS $0.84 flat; guides FY2022 adj EPS $3.27-3.35
Q4 reported revenue $405.5M (+4.3% reported, +8.3% organic); GAAP EPS $0.53 vs $1.09 (prior-year $59.2M tax benefit); adjusted EPS $0.84 flat.
On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").
Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
On November 4, 2024, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Mojdeh Poul to serve as its President and Chief Executive Officer.
On February 27, 2024, the Company’s Board of Directors appointed Stuart M. Essig, Ph.D., the Company’s Chairman, to the role of Executive Chairman, effective immediately.
On February 27, 2024, Jan De Witte informed Integra LifeSciences Holdings Corporation (the “Company”) of his intention to retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process.
On December 12, 2023, the Board of Directors (“Board”) of Integra LifeSciences Holdings Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance committee of the Board, appointed Jeffrey Alan Graves as a director of the Company, effective immediately, to fill an existing vacancy on the Board.
On June 21, 2023, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Lea Daniels Knight to serve as its Executive Vice President and Chief Financial Officer effective June 28, 2023.
On January 25, 2023, Carrie Anderson, Chief Financial Officer of Integra LifeSciences Holdings Corporation (the “Company”), notified the Company of her decision to resign, effective as of February 2, 2023, to pursue another professional opportunity.
In the interim, Mathieu P. Aussermeier, Vice President, Corporate Finance, Investor Relations & Treasurer, and Jeffrey Mosebrook, Senior Vice President, Finance, will assume Ms. Anderson’s financial duties and responsibilities and report to Jan De Witte, the Company’s President and Chief Executive Officer.
In the interim, Mathieu P. Aussermeier, Vice President, Corporate Finance, Investor Relations & Treasurer, and Jeffrey Mosebrook, Senior Vice President, Finance, will assume Ms. Anderson’s financial duties and responsibilities and report to Jan De Witte, the Company’s President and Chief Executive Officer.
As previously disclosed, on August 25, 2022, Integra LifeSciences Holdings Corporation (the “Company”) announced the elimination of the position of Chief Operating Officer and the separation of Glenn Coleman, the Company’s Chief Operating Officer, from the Company.
Max materiality 0.85 · Median 0.65 · Most common event earnings